Evidence map›Paper›PMID 31956380›Full record

ArticleHereditary cancer in clinical practice2020

Whole-body MRI within a surveillance program for carriers with clinically actionable germline

Meis Omran, Lennart Blomqvist, Yvonne Brandberg, Niklas Pal, Per Kogner, Anne Kinhult Ståhlbom, Emma Tham, Svetlana Bajalica-Lagercrantz

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Hereditary cancer in clinical practice, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Observational
  2. Article
  3. Whole-body MRI for cancer surveillance in ataxia-telangiectasia: A qualitative study of the perspectives of people affected by A-T and their families.Health expectations : an international journal of public participation in health care and health policy · 2023
    Article
  4. Cancers · 2022
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Meis Omran1Department of Oncology-Pathology, Karolinska Institutet SE-171 77 Stockholm, Sweden AND Cancer Theme, Karolinska University Hospital, Solna, SE-171 76 Stockholm, Sweden.ORCID 0000-0001-5485-6566
Lennart Blomqvist2Department of Molecular Medicine and Surgery, Karolinska Institutet, SE-171 77 Stockholm, Sweden.ORCID https://orcid.org/0000-0003-1716-2439
Yvonne Brandberg4Department of Oncology-Pathology, Karolinska Institutet, SE-171 64 Stockholm, Sweden.ORCID https://orcid.org/0000-0001-9840-9266
Niklas Pal5Department of Women's and Children's Health, Karolinska Institutet, SE-171 77 Stockholm, Sweden.ORCID https://orcid.org/0000-0001-8066-5843
Per Kogner5Department of Women's and Children's Health, Karolinska Institutet, SE-171 77 Stockholm, Sweden.ORCID https://orcid.org/0000-0002-2202-9694
Anne Kinhult Ståhlbom7Cancer Theme, Karolinska University Hospital, Solna, SE-171 76 Stockholm, Sweden.
Emma Tham *8Department of Molecular Medicine and Surgery, Karolinska Institutet, SE-171 77 Stockholm, Sweden.ORCID https://orcid.org/0000-0001-6079-164X
Svetlana Bajalica-Lagercrantz *1Department of Oncology-Pathology, Karolinska Institutet SE-171 77 Stockholm, Sweden AND Cancer Theme, Karolinska University Hospital, Solna, SE-171 76 Stockholm, Sweden.ORCID https://orcid.org/0000-0002-7175-7102
Karolinska University Hospital · SEKarolinska Institutet · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe current guidelines in Sweden regarding individuals with a clinically actionable (i.e. pathogenic or likely pathogenic) germline

methodsThe study comprises a patient registry (mandatory for all participants) and three optional parts: a biobank, a surveillance program and a psychosocial evaluation of the surveillance. All known adult eligible carriers regardless of age are offered to take part of the surveillance program offering MRI yearly of the whole-body, breast, and brain as well as breast ultrasound. A special surveillance program is offered for individuals 15-18 years old with a 50% risk of being a mutation carrier or with a verified

resultsTo date, a total of 41 adults and 11 children have been included in the study.

conclusionsThe SWEP53 is the first structured national surveillance program including radiological and clinical routines for

trial registrationTrial registration number: ISRCTN13103571, retrospectively registered on 14/10/2019.

Indexed as

Germline TP53 mutationHereditary breast cancerLiFraumeni syndromePathological variantSurveillance program

Identifiers

PMID31956380
PMCPMC6958585
OpenAlexW3006196213

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.